查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1424963

移植诊断的全球市场：按技术、提供的内容、移植类型、应用和最终用户划分的市场规模和份额分析 - 工业需求预测（截至 2030 年）

Transplant Diagnostics Market Size and Share Analysis by Technology, Offering, Transplant Type, Application, End User - Global Industry Demand Forecast to 2030
出版日期: | 出版商: Prescient & Strategic Intelligence | 英文 340 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年全球移植诊断市场价值将达到46.867亿美元，到2029年底成长率为7.5%，到2030年将达到77.135亿美元。

这是由于器官替代手术的需求不断增加、器官替代手术前诊断程序的需求不断增加以及传染病的增加。

此外，晚期器官衰竭的患者数量正在增加，器官移植手术的进步使许多患者能够接受这些手术。

从技术角度来看，分子检测将在 2023 年以 65% 的份额引领产业，并且预计将继续占据主导地位。

这是因为分子检测广泛应用于术前诊断过程中，以测试受者和供者的相容性。 与非分子检测相比，这些检测方法之所以获得认可，主要是因为它们具有技术优势，例如可以研究大量样品、即时分析以及较高的程序有效性。

软体和服务业预计未来成长最快。 这是因为在竞争激烈的市场中各公司定期提供软体更新和全面的服务。

此外，随着更先进设备的扩展，对技术人员如何处理和使用设备的培训课程的需求正在迅速增加。 这些因素正在推动产业的发展。

到2023年，诊断药物类别将占据移植诊断市场70%的份额，而这一趋势预计将持续下去。 这是因为这种疾病的发生率正在增加。

此外，诊断类别分为移植前诊断和移植后诊断。 此外，在移植过程中，所有相关的诊断测试均在移植前进行，以确认移植物的适用性。 例子包括血液分析、组织相容性测试和传染病测试。

到 2023 年，北美将占据最大份额，达到 50%，而这一趋势预计将持续下去。 这与最先进的技术和分析工具的高接受率、高昂的医疗成本、熟练的专业人员的可用性以及软组织移植、干细胞治疗和个人化药物的广泛使用有很大关係。

此外，器官移植数量的增加、移植意识的提高、传染病患者病率的增加以及更容易患慢性病的老年人口的增加推动了该行业的发展。

本报告分析了全球移植诊断市场，包括市场的基本结构和最新情况、主要促进和抑制因素以及全球、按地区和主要国家的市场规模前景（以货币形式计算） （2017-2030），我们正在按技术、供应内容、连接埠类型、应用程式和最终用户、市场竞争现状以及主要公司概况来调查详细趋势。

目录

第一章研究范围

第二章研究方法

第 3 章执行摘要

第 4 章市场指标

第五章产业展望

  • 市场动态
    • 趋势
    • 促进因素
    • 抑制因素/挑战
    • 促进/抑制因子影响分析
  • 新型冠状病毒感染 (COVID-19) 的影响
  • 波特五力分析

第六章世界市场

  • 摘要
  • 市场收入：依技术划分（2017-2030 年）
    • 按类型划分的分子检测市场收入（2017-2030 年）
    • 按类型划分的非分子检测市场收入（2017-2030 年）
  • 市场收入：依产品划分（2017-2030 年）
  • 市场收入：依移植类型分类（2017-2030 年）
    • 实体器官市场收入：按类型划分（2017-2030 年）
  • 市场收入：依应用分类（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）
  • 市场收入：按地区划分（2017-2030 年）

第七章北美市场

  • 摘要
  • 市场收入：依技术划分（2017-2030 年）
    • 按类型划分的分子检测市场收入（2017-2030 年）
    • 按类型划分的非分子检测市场收入（2017-2030 年）
  • 市场收入：依产品划分（2017-2030 年）
  • 市场收入：依移植类型分类（2017-2030 年）
    • 实体器官市场收入：按类型划分（2017-2030 年）
  • 市场收入：依应用分类（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）
  • 市场收入：依国家/地区划分（2017-2030 年）

第8章欧洲市场

第9章亚太市场

第10章拉丁美洲市场

第 11 章中东与非洲 (MEA) 市场

第12章美国市场

  • 摘要
  • 市场收入：依技术划分（2017-2030 年）
    • 按类型划分的分子检测市场收入（2017-2030 年）
    • 按类型划分的非分子检测市场收入（2017-2030 年）
  • 市场收入：依产品划分（2017-2030 年）
  • 市场收入：依移植类型分类（2017-2030 年）
    • 实体器官市场收入：按类型划分（2017-2030 年）
  • 市场收入：依应用分类（2017-2030 年）
  • 市场收入：以最终用户划分（2017-2030 年）

第十三章加拿大市场

第14章德国市场

第十五章法国市场

第十六章英国市场

第十七章义大利市场

第十八章西班牙市场

第十九章日本市场

第20章中国市场

第21章印度市场

第22章澳洲市场

第23章韩国市场

第24章巴西市场

第25章墨西哥市场

第26章沙乌地阿拉伯市场

第27章南非市场

第 28 章阿联酋 (UAE) 市场

第29章竞争态势

  • 市场参与者及其提供的产品/服务列表
  • 主要公司的竞争基准
  • 各大公司的产品基准
  • 近期策略发展状况

第30章公司简介

  • bioMerieux S.A.
  • Thermo Fisher Scientific Inc.
  • Bio-Rad Laboratories Inc.
  • Abbott Laboratories
  • Hologic Inc.
  • F. Hoffmann-La Roche Ltd.
  • Laboratory Corporation of America Holdings
  • BAG Diagnostics GmbH
  • Illumina Inc.

第31章附录

简介目录
Product Code: 11958

The transplant diagnostics market was valued at USD 4,686.7 million in 2023, and it will grow at a rate of 7.5% by the end of this decade, to touch USD 7,713.5 million by 2030.

This is attributable to the growing requirement for organ replacement procedures, the growing requirement for diagnostic procedures before organ replacement, and the powering occurrence of communicable diseases.

Also, the number of people with final-stage organ failure is on the rise, and because of the development in organ transplantation procedures, a high number of patients can now access these surgeries.

On the basis of technology, molecular assay led the industry with a share, of 65%, in 2023, and it will continue to dominate in the future as well.

This is due to the fact that molecular assays are extensively used in presurgical diagnostic processes for testing the compatibility of a recipient and donor. These assays are mostly accepted because of their tech benefits as opposed to non-molecular assays, for example the study of numerous samples and instantaneous analysis and high procedural efficacy.

The software & services category will grow the fastest in the future. This is because of the regular updates in software and enhanced services provided by the market players remain in the competition.

Furthermore, the expansion of more progressive instruments has led to a surge in the demand for training sessions to teach technical employees to handle and use an instrument. These factors led to the evolution of the industry.

The diagnostics category dominated the transplant diagnostics market, with a share of 70%, in 2023, and it will continue like this in the future. This is credited to the increasing occurrence of ailments.

Furthermore, the diagnostic category is divided into pre-transplantation and post-transplantation diagnostic. Additionally, for transplant processes, all relative diagnostic tests will be done prior to the transplant to see the compatibility of the transplant for example blood profiling, histocompatibility testing, and communicable disease testing.

North America had the largest share, of 50%, in 2023, and it will continue like this in the future. This has a lot to do with the high acceptance rate of cutting-edge techniques and analytic tools, high healthcare spending, the obtainability of skilled experts, and the extensive use of soft tissue transplants, stem cell therapies, and tailored medications.

Furthermore, the growing count of organ replacements, the increasing consciousness of transplantation, the growing incidence of communicable ailments, and the rising elderly populace susceptible to chronic ailments are powering the industry.

There is an increasing number of organ transplants happening around the world, and this will power the demand for transplant diagnostic solutions. The trend will continue in the years to come as well.

Top Providers of Transplant Diagnostics Are:

bioMerieux S.A.

Thermo Fisher Scientific Inc.

Bio-Rad Laboratories, Inc.

Abbott Laboratories

Hologic Inc.

F. Hoffmann-La Roche Ltd.

Laboratory Corporation of America Holdings

BAG Diagnostics GmbH

Illumina Inc.

Table of Contents

Chapter 1. Research Scope

  • 1.1. Research Objectives
  • 1.2. Market Definition
  • 1.3. Analysis Period
  • 1.4. Market Size Breakdown by Segments
    • 1.4.1. Market size breakdown, by technology
    • 1.4.2. Market size breakdown, by offering
    • 1.4.3. Market size breakdown, by transplant type
    • 1.4.4. Market size breakdown, by end user
    • 1.4.5. Market size breakdown, by application
    • 1.4.6. Market size breakdown, by region
    • 1.4.7. Market size breakdown, by country
  • 1.5. Market Data Reporting Unit
    • 1.5.1. Value
  • 1.6. Key Stakeholders

Chapter 2. Research Methodology

  • 2.1. Secondary Research
    • 2.1.1. Paid
    • 2.1.2. Unpaid
    • 2.1.3. P&S Intelligence database
  • 2.2. Primary Research
  • 2.3. Market Size Estimation
  • 2.4. Data Triangulation
  • 2.5. Currency Conversion Rates
  • 2.6. Assumptions for the Study
  • 2.7. Notes and Caveats

Chapter 3. Executive Summary

Chapter 4. Market Indicators

Chapter 5. Industry Outlook

  • 5.1. Market Dynamics
    • 5.1.1. Trends
    • 5.1.2. Drivers
    • 5.1.3. Restraints/challenges
    • 5.1.4. Impact analysis of drivers/restraints
  • 5.2. Impact of COVID-19
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Bargaining power of buyers
    • 5.3.2. Bargaining power of suppliers
    • 5.3.3. Threat of new entrants
    • 5.3.4. Intensity of rivalry
    • 5.3.5. Threat of substitutes

Chapter 6. Global Market

  • 6.1. Overview
  • 6.2. Market Revenue, by Technology (2017-2030)
    • 6.2.1. Molecular assay market revenue, by type (2017-2030)
    • 6.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 6.3. Market Revenue, by Offering (2017-2030)
  • 6.4. Market Revenue, by Transplant Type (2017-2030)
    • 6.4.1. Solid organ market revenue, by type (2017-2030)
  • 6.5. Market Revenue, by Application (2017-2030)
  • 6.6. Market Revenue, by End User (2017-2030)
  • 6.7. Market Revenue, by Region (2017-2030)

Chapter 7. North America Market

  • 7.1. Overview
  • 7.2. Market Revenue, by Technology (2017-2030)
    • 7.2.1. Molecular assay market revenue, by type (2017-2030)
    • 7.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 7.3. Market Revenue, by Offering (2017-2030)
  • 7.4. Market Revenue, by Transplant Type (2017-2030)
    • 7.4.1. Solid organ market revenue, by type (2017-2030)
  • 7.5. Market Revenue, by Application (2017-2030)
  • 7.6. Market Revenue, by End User (2017-2030)
  • 7.7. Market Revenue, by Country (2017-2030)

Chapter 8. Europe Market

  • 8.1. Overview
  • 8.2. Market Revenue, by Technology (2017-2030)
    • 8.2.1. Molecular assay market revenue, by type (2017-2030)
    • 8.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 8.3. Market Revenue, by Offering (2017-2030)
  • 8.4. Market Revenue, by Transplant Type (2017-2030)
    • 8.4.1. Solid organ market revenue, by type (2017-2030)
  • 8.5. Market Revenue, by Application (2017-2030)
  • 8.6. Market Revenue, by End User (2017-2030)
  • 8.7. Market Revenue, by Country (2017-2030)

Chapter 9. APAC Market

  • 9.1. Overview
  • 9.2. Market Revenue, by Technology (2017-2030)
    • 9.2.1. Molecular assay market revenue, by type (2017-2030)
    • 9.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 9.3. Market Revenue, by Offering (2017-2030)
  • 9.4. Market Revenue, by Transplant Type (2017-2030)
    • 9.4.1. Solid organ market revenue, by type (2017-2030)
  • 9.5. Market Revenue, by Application (2017-2030)
  • 9.6. Market Revenue, by End User (2017-2030)
  • 9.7. Market Revenue, by Country (2017-2030)

Chapter 10. LATAM Market

  • 10.1. Overview
  • 10.2. Market Revenue, by Technology (2017-2030)
    • 10.2.1. Molecular assay market revenue, by type (2017-2030)
    • 10.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 10.3. Market Revenue, by Offering (2017-2030)
  • 10.4. Market Revenue, by Transplant Type (2017-2030)
    • 10.4.1. Solid organ market revenue, by type (2017-2030)
  • 10.5. Market Revenue, by Application (2017-2030)
  • 10.6. Market Revenue, by End User (2017-2030)
  • 10.7. Market Revenue, by Country (2017-2030)

Chapter 11. MEA Market

  • 11.1. Overview
  • 11.2. Market Revenue, by Technology (2017-2030)
    • 11.2.1. Molecular assay market revenue, by type (2017-2030)
    • 11.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 11.3. Market Revenue, by Offering (2017-2030)
  • 11.4. Market Revenue, by Transplant Type (2017-2030)
    • 11.4.1. Solid organ market revenue, by type (2017-2030)
  • 11.5. Market Revenue, by Application (2017-2030)
  • 11.6. Market Revenue, by End User (2017-2030)
  • 11.7. Market Revenue, by Country (2017-2030)

Chapter 12. U.S. Market

  • 12.1. Overview
  • 12.2. Market Revenue, by Technology (2017-2030)
    • 12.2.1. Molecular assay market revenue, by type (2017-2030)
    • 12.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 12.3. Market Revenue, by Offering (2017-2030)
  • 12.4. Market Revenue, by Transplant Type (2017-2030)
    • 12.4.1. Solid organ market revenue, by type (2017-2030)
  • 12.5. Market Revenue, by Application (2017-2030)
  • 12.6. Market Revenue, by End User (2017-2030)

Chapter 13. Canada Market

  • 13.1. Overview
  • 13.2. Market Revenue, by Technology (2017-2030)
    • 13.2.1. Molecular assay market revenue, by type (2017-2030)
    • 13.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 13.3. Market Revenue, by Offering (2017-2030)
  • 13.4. Market Revenue, by Transplant Type (2017-2030)
    • 13.4.1. Solid organ market revenue, by type (2017-2030)
  • 13.5. Market Revenue, by Application (2017-2030)
  • 13.6. Market Revenue, by End User (2017-2030)

Chapter 14. Germany Market

  • 14.1. Overview
  • 14.2. Market Revenue, by Technology (2017-2030)
    • 14.2.1. Molecular assay market revenue, by type (2017-2030)
    • 14.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 14.3. Market Revenue, by Offering (2017-2030)
  • 14.4. Market Revenue, by Transplant Type (2017-2030)
    • 14.4.1. Solid organ market revenue, by type (2017-2030)
  • 14.5. Market Revenue, by Application (2017-2030)
  • 14.6. Market Revenue, by End User (2017-2030)

Chapter 15. France Market

  • 15.1. Overview
  • 15.2. Market Revenue, by Technology (2017-2030)
    • 15.2.1. Molecular assay market revenue, by type (2017-2030)
    • 15.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 15.3. Market Revenue, by Offering (2017-2030)
  • 15.4. Market Revenue, by Transplant Type (2017-2030)
    • 15.4.1. Solid organ market revenue, by type (2017-2030)
  • 15.5. Market Revenue, by Application (2017-2030)
  • 15.6. Market Revenue, by End User (2017-2030)

Chapter 16. U.K. Market

  • 16.1. Overview
  • 16.2. Market Revenue, by Technology (2017-2030)
    • 16.2.1. Molecular assay market revenue, by type (2017-2030)
    • 16.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 16.3. Market Revenue, by Offering (2017-2030)
  • 16.4. Market Revenue, by Transplant Type (2017-2030)
    • 16.4.1. Solid organ market revenue, by type (2017-2030)
  • 16.5. Market Revenue, by Application (2017-2030)
  • 16.6. Market Revenue, by End User (2017-2030)

Chapter 17. Italy Market

  • 17.1. Overview
  • 17.2. Market Revenue, by Technology (2017-2030)
    • 17.2.1. Molecular assay market revenue, by type (2017-2030)
    • 17.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 17.3. Market Revenue, by Offering (2017-2030)
  • 17.4. Market Revenue, by Transplant Type (2017-2030)
    • 17.4.1. Solid organ market revenue, by type (2017-2030)
  • 17.5. Market Revenue, by Application (2017-2030)
  • 17.6. Market Revenue, by End User (2017-2030)

Chapter 18. Spain Market

  • 18.1. Overview
  • 18.2. Market Revenue, by Technology (2017-2030)
    • 18.2.1. Molecular assay market revenue, by type (2017-2030)
    • 18.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 18.3. Market Revenue, by Offering (2017-2030)
  • 18.4. Market Revenue, by Transplant Type (2017-2030)
    • 18.4.1. Solid organ market revenue, by type (2017-2030)
  • 18.5. Market Revenue, by Application (2017-2030)
  • 18.6. Market Revenue, by End User (2017-2030)

Chapter 19. Japan Market

  • 19.1. Overview
  • 19.2. Market Revenue, by Technology (2017-2030)
    • 19.2.1. Molecular assay market revenue, by type (2017-2030)
    • 19.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 19.3. Market Revenue, by Offering (2017-2030)
  • 19.4. Market Revenue, by Transplant Type (2017-2030)
    • 19.4.1. Solid organ market revenue, by type (2017-2030)
  • 19.5. Market Revenue, by Application (2017-2030)
  • 19.6. Market Revenue, by End User (2017-2030)

Chapter 20. China Market

  • 20.1. Overview
  • 20.2. Market Revenue, by Technology (2017-2030)
    • 20.2.1. Molecular assay market revenue, by type (2017-2030)
    • 20.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 20.3. Market Revenue, by Offering (2017-2030)
  • 20.4. Market Revenue, by Transplant Type (2017-2030)
    • 20.4.1. Solid organ market revenue, by type (2017-2030)
  • 20.5. Market Revenue, by Application (2017-2030)
  • 20.6. Market Revenue, by End User (2017-2030)

Chapter 21. India Market

  • 21.1. Overview
  • 21.2. Market Revenue, by Technology (2017-2030)
    • 21.2.1. Molecular assay market revenue, by type (2017-2030)
    • 21.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 21.3. Market Revenue, by Offering (2017-2030)
  • 21.4. Market Revenue, by Transplant Type (2017-2030)
    • 21.4.1. Solid organ market revenue, by type (2017-2030)
  • 21.5. Market Revenue, by Application (2017-2030)
  • 21.6. Market Revenue, by End User (2017-2030)

Chapter 22. Australia Market

  • 22.1. Overview
  • 22.2. Market Revenue, by Technology (2017-2030)
    • 22.2.1. Molecular assay market revenue, by type (2017-2030)
    • 22.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 22.3. Market Revenue, by Offering (2017-2030)
  • 22.4. Market Revenue, by Transplant Type (2017-2030)
    • 22.4.1. Solid organ market revenue, by type (2017-2030)
  • 22.5. Market Revenue, by Application (2017-2030)
  • 22.6. Market Revenue, by End User (2017-2030)

Chapter 23. South Korea Market

  • 23.1. Overview
  • 23.2. Market Revenue, by Technology (2017-2030)
    • 23.2.1. Molecular assay market revenue, by type (2017-2030)
    • 23.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 23.3. Market Revenue, by Offering (2017-2030)
  • 23.4. Market Revenue, by Transplant Type (2017-2030)
    • 23.4.1. Solid organ market revenue, by type (2017-2030)
  • 23.5. Market Revenue, by Application (2017-2030)
  • 23.6. Market Revenue, by End User (2017-2030)

Chapter 24. Brazil Market

  • 24.1. Overview
  • 24.2. Market Revenue, by Technology (2017-2030)
    • 24.2.1. Molecular assay market revenue, by type (2017-2030)
    • 24.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 24.3. Market Revenue, by Offering (2017-2030)
  • 24.4. Market Revenue, by Transplant Type (2017-2030)
    • 24.4.1. Solid organ market revenue, by type (2017-2030)
  • 24.5. Market Revenue, by Application (2017-2030)
  • 24.6. Market Revenue, by End User (2017-2030)

Chapter 25. Mexico Market

  • 25.1. Overview
  • 25.2. Market Revenue, by Technology (2017-2030)
    • 25.2.1. Molecular assay market revenue, by type (2017-2030)
    • 25.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 25.3. Market Revenue, by Offering (2017-2030)
  • 25.4. Market Revenue, by Transplant Type (2017-2030)
    • 25.4.1. Solid organ market revenue, by type (2017-2030)
  • 25.5. Market Revenue, by Application (2017-2030)
  • 25.6. Market Revenue, by End User (2017-2030)

Chapter 26. Saudi Arabia Market

  • 26.1. Overview
  • 26.2. Market Revenue, by Technology (2017-2030)
    • 26.2.1. Molecular assay market revenue, by type (2017-2030)
    • 26.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 26.3. Market Revenue, by Offering (2017-2030)
  • 26.4. Market Revenue, by Transplant Type (2017-2030)
    • 26.4.1. Solid organ market revenue, by type (2017-2030)
  • 26.5. Market Revenue, by Application (2017-2030)
  • 26.6. Market Revenue, by End User (2017-2030)

Chapter 27. South Africa Market

  • 27.1. Overview
  • 27.2. Market Revenue, by Technology (2017-2030)
    • 27.2.1. Molecular assay market revenue, by type (2017-2030)
    • 27.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 27.3. Market Revenue, by Offering (2017-2030)
  • 27.4. Market Revenue, by Transplant Type (2017-2030)
    • 27.4.1. Solid organ market revenue, by type (2017-2030)
  • 27.5. Market Revenue, by Application (2017-2030)
  • 27.6. Market Revenue, by End User (2017-2030)

Chapter 28. U.A.E. Market

  • 28.1. Overview
  • 28.2. Market Revenue, by Technology (2017-2030)
    • 28.2.1. Molecular assay market revenue, by type (2017-2030)
    • 28.2.2. Non-molecular assay market revenue, by type (2017-2030)
  • 28.3. Market Revenue, by Offering (2017-2030)
  • 28.4. Market Revenue, by Transplant Type (2017-2030)
    • 28.4.1. Solid organ market revenue, by type (2017-2030)
  • 28.5. Market Revenue, by Application (2017-2030)
  • 28.6. Market Revenue, by End User (2017-2030)

Chapter 29. Competitive Landscape

  • 29.1. List of Market Players and their Offerings
  • 29.2. Competitive Benchmarking of Key Players
  • 29.3. Product Benchmarking of Key Players
  • 29.4. Recent Strategic Developments

Chapter 30. Company Profiles

  • 30.1. bioMerieux S.A.
    • 30.1.1. Business overview
    • 30.1.2. Product and service offerings
    • 30.1.3. Key financial summary
  • 30.2. Thermo Fisher Scientific Inc.
    • 30.2.1. Business overview
    • 30.2.2. Product and service offerings
    • 30.2.3. Key financial summary
  • 30.3. Bio-Rad Laboratories Inc.
    • 30.3.1. Business overview
    • 30.3.2. Product and service offerings
    • 30.3.3. Key financial summary
  • 30.4. Abbott Laboratories
    • 30.4.1. Business overview
    • 30.4.2. Product and service offerings
    • 30.4.3. Key financial summary
  • 30.5. Hologic Inc.
    • 30.5.1. Business overview
    • 30.5.2. Product and service offerings
    • 30.5.3. Key financial summary
  • 30.6. F. Hoffmann-La Roche Ltd.
    • 30.6.1. Business overview
    • 30.6.2. Product and service offerings
    • 30.6.3. Key financial summary
  • 30.7. Laboratory Corporation of America Holdings
    • 30.7.1. Business overview
    • 30.7.2. Product and service offerings
    • 30.7.3. Key financial summary
  • 30.8. BAG Diagnostics GmbH
    • 30.8.1. Business overview
    • 30.8.2. Product and service offerings
    • 30.8.3. Key financial summary
  • 30.9. Illumina Inc.
    • 30.9.1. Business overview
    • 30.9.2. Product and service offerings
    • 30.9.3. Key financial summary

Chapter 31. Appendix

  • 31.1. Abbreviations
  • 31.2. Sources and References
  • 31.3. Related Reports